Phase 2 N=37 An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome
Primary: Percentage of Participants With Response — 23.5 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=62 Efficacy of Repyflec Cognitive Remediation Group Training in Schizophrenia
Indication for Modification of Patient Cognitive Status
Primary: Executive Function — 99.5; 95.7; 2.7; 1.7 units on a scale — p=<0.05
Phase 2 N=81 Study of E7389 for Advanced or Metastatic Breast Cancer
Breast Cancer
Primary: Number of Subjects With Adverse Events. — 81 Participants
Phase 1 N=80 Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents
Bacteriuria
Primary: E.Coli Bacteriuria Plus Pyuria — 33; 29; 23; 25 urine cultures and urinalyses
Phase 2 N=47 An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
Prostate Neoplasms
Primary: Percentage of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12 — 36.2 percentage of participants
Phase 3 N=1,577 Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours (h) Post-dose at Day 168 — -0.012; 0.034; 0.029; 0.173 Liters — p=0.085
N/A N=103 Evaluation of the Ulthera™ System for Obtaining Lift and Tightening of the Cheek Tissue
Mild to Moderate Skin Laxity on Cheek · Mild to Moderate Skin Laxity on Upper Neck · Mild to Moderate Subcutaneous Fat on Cheek
Primary: Change in Overall Lifting and Tightening of Treated Tissue on the Lower Face and Submental Regions. — 68.60 percentage of participants improved
N/A N=1,014 A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events (AEs) — 142; 3; 27 participants
Phase 2 N=4 Enhancing Attention in Adults With Compulsive Hoarding
Hoarding Disorder
Primary: Number of Patients Who Met and Exceeded Response Criteria of Attention Deficit Hyperactivity Disorder Symptom Scale — 4 participants
Phase 2 N=296 Effect of CPP-ACP Paste on Dental Caries in Primary Teeth
Dental Caries
Primary: the Mean Number of Enamel Carious Lesion — 13.69; 14.55 Surfaces
Phase 3 N=60 Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
Urea Cycle Disorders
Primary: Rate of Adverse Events (Number of Participants Who Experienced Any AE Considered Related to Study Drug) — 33 participants
Phase 4 N=38 The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
Type 2 Diabetes
Primary: Total Disposition Index — 332; 253; 519; 310 DItot (10^-14 dl/kg/min^2 per pmol/l)
Phase 3 N=1,390 A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours Post-dose at Day 168 — 0.026; 0.080; 0.129; 0.218 Liters — p=0.040
Phase 3 N=221 Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
Lupus Erythematosus, Systemic
Primary: Change in Mean-Mean Common Carotid IMT (CIMT) — 0.0010; 0.0024 mm
Phase 2 N=13 Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency
Interdental Papillary Insufficiency
Primary: Number of Responders Based on the Average Investigator Evaluation of Change From Baseline for All Treated Areas on the Global Ordinal Rating Scale (GORS) — 10 participants